
With construction well underway on a $250 million expansion in Bloomington, New Jersey-based Simtra BioPharma is furthering its growth efforts with plans for another facility nearby.
The pharmaceutical contract development and manufacturing organization said Friday it has acquired a 65-acre property near its existing manufacturing facility from Bloomington-based Cook Group.
Simtra did not disclose the purchase price for the acquisition, but said the property at 301 N. Curry Pike has more than 300,000 square feet of space for expansion of its operations.
The company said in a news release that it is evaluating a project to design and install manufacturing lines at the site, including its first U.S.-based, commercial-scale capacity for oncology-focused injectable drug products.
“This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in North America,” CEO Franco Negron said. “It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains.”
Specifically, the facility would run vial and prefilled syringe filling lines, Simtra said. An estimated number of new jobs was not provided.
The company said it will be working with Monroe County officials on a phased development plan, with additional details expected in the coming weeks.
Simtra BioPharma operates a sterile fill/finish manufacturing campus at 927 South Curry Pike in Bloomington, which makes pre-filled medical syringes and vials. The company broke ground on a $250 million, 150,000-square-foot expansion of that facility in June 2024 that is expected to bring 130 new jobs.
The company also recently completed a new, more than $100 million production facility in Germany. Simtra employs nearly 1,900 people across its global footprint, including just over 1,100 in the U.S., the majority of whom are in Bloomington.
